These statements have not been evaluated by the Food and Drug Administration (FDA). If you are searching to buy Noopept (Omberacetam) 10mg USA, please note that Aptechka.store provides 100% original Noopept 10 mg 50 tablets | Advanced Peptide Memory Enhancer | Cognitive Focus & Mental Clarity Support for personal use. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your attending physician strictly before starting any new protocol.
Product Properties
Storage Temp
Store protected from light at or below 77°F (25°C)
Nursing Mothers
Contraindicated during breastfeeding
Pregnancy
Contraindicated during pregnancy
Allergy Sufferers
Contraindicated with hypersensitivity to the active ingredient or any excipient
Driving & Machinery
Use caution with tasks requiring rapid psychomotor reactions
Directions
Active Ingredient
Omberacetam (Noopept) — 10.0 mg per tablet.
Omberacetam (Noopept) — 10.0 mg per tablet.
Dosage Form
White, round, flat-cylindrical tablets with a bevel.
White, round, flat-cylindrical tablets with a bevel.
Composition
Per 1 tablet:
Per 1 tablet:
- Active ingredient: Omberacetam (Noopept) — 10.0 mg;
- Excipients: Lactose monohydrate — 55.0 mg, potato starch — 13.5 mg, microcrystalline cellulose 101 — 21.2 mg, magnesium stearate — 0.3 mg, povidone (polyvinylpyrrolidone, povidone K-25) — 0.0008 mg.
Pharmacotherapeutic Group
Nootropic agent.
Nootropic agent.
Indications
Memory, attention, and other cognitive function impairments, as well as emotionally labile disorders (including in elderly patients) in:
Memory, attention, and other cognitive function impairments, as well as emotionally labile disorders (including in elderly patients) in:
- Consequences of traumatic brain injury;
- Post-concussion syndrome;
- Vascular cerebral insufficiency (encephalopathies of various origins);
- Asthenic disorders;
- Other conditions with signs of reduced intellectual productivity.
Many patients who buy noopept (omberacetam) 10mg usa do so for these indications, but the drug should be used only as prescribed by a physician.
Dosage and Administration
Noopept® is taken orally, after meals. Treatment begins with a dose of 20 mg, divided into two doses of 10 mg during the day (morning and afternoon). If the therapy is insufficiently effective and the drug is well tolerated, the dose is increased to 30 mg (see “Special Instructions”), divided into three doses of 10 mg during the day. The drug should not be taken later than 6 p.m. The duration of the course treatment is 1.5–3 months. A repeated course of treatment, if necessary, may be carried out after 1 month. Always follow the standard dosage guidelines if you choose to buy noopept (omberacetam) 10mg usa for cognitive support.
Noopept® is taken orally, after meals. Treatment begins with a dose of 20 mg, divided into two doses of 10 mg during the day (morning and afternoon). If the therapy is insufficiently effective and the drug is well tolerated, the dose is increased to 30 mg (see “Special Instructions”), divided into three doses of 10 mg during the day. The drug should not be taken later than 6 p.m. The duration of the course treatment is 1.5–3 months. A repeated course of treatment, if necessary, may be carried out after 1 month. Always follow the standard dosage guidelines if you choose to buy noopept (omberacetam) 10mg usa for cognitive support.
Contraindications
- Pregnancy, breastfeeding period;
- Age under 18 years;
- Hypersensitivity to the components of the drug;
- Lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
- Severe impairment of liver and kidney function.
Use during pregnancy and breastfeeding: The drug is contraindicated during pregnancy. If the use of the drug during breastfeeding is necessary, the question of stopping breastfeeding should be decided. It is critical to review all contraindications before you buy noopept (omberacetam) 10mg usa online.
Special Instructions
If it is necessary to increase the dose of the drug (up to 30 mg/day), with long-term use, as well as with simultaneous use with other drugs, the appearance of adverse reactions, or worsening of the condition, a physician should be consulted.
If it is necessary to increase the dose of the drug (up to 30 mg/day), with long-term use, as well as with simultaneous use with other drugs, the appearance of adverse reactions, or worsening of the condition, a physician should be consulted.
Effect on ability to drive vehicles and mechanisms: Noopept® does not affect the ability to drive mechanisms and vehicles.
Side Effects
Allergic reactions are possible. In patients with arterial hypertension, mainly of severe degree, an increase in blood pressure may be observed during the drug intake.
Allergic reactions are possible. In patients with arterial hypertension, mainly of severe degree, an increase in blood pressure may be observed during the drug intake.
Interaction with Other Medicinal Products
No interaction of Noopept® with alcohol, hypnotics, antihypertensive drugs, and psychostimulant drugs has been established.
No interaction of Noopept® with alcohol, hypnotics, antihypertensive drugs, and psychostimulant drugs has been established.
Pharmacodynamics
Noopept® possesses nootropic and neuroprotective properties. It improves learning ability and memory, acting on all phases of processing: initial information processing, consolidation, and retrieval. It prevents the development of amnesia caused by electroshock, blockade of central cholinergic structures, glutamatergic receptor systems, and deprivation of the paradoxical sleep phase.
Noopept® possesses nootropic and neuroprotective properties. It improves learning ability and memory, acting on all phases of processing: initial information processing, consolidation, and retrieval. It prevents the development of amnesia caused by electroshock, blockade of central cholinergic structures, glutamatergic receptor systems, and deprivation of the paradoxical sleep phase.
The neuroprotective (protective) action of Noopept® is manifested in increasing the resistance of brain tissue to damaging effects (trauma, hypoxia, electroconvulsive, toxic) and weakening the degree of damage to brain neurons. The drug reduces the volume of the lesion in a thrombotic model of stroke and prevents neuronal death in tissue culture of the cerebral cortex and cerebellum exposed to neurotoxic concentrations of glutamate and free-radical oxygen. Noopept® has an antioxidant effect, blocks potential-dependent calcium channels of neurons, weakening the neurotoxic effect of excess calcium, improves the rheological properties of blood, possessing antiplatelet, fibrinolytic, and anticoagulant properties.
The nootropic effect of the drug is associated with the formation of cycloprolylglycine, similar in structure to the endogenous cyclic dipeptide possessing anti-amnestic activity, as well as with the presence of a cholinopositive action. Noopept® increases the amplitude of the transcallosal response, facilitating associative connections between the cerebral hemispheres at the level of cortical structures.
It promotes the restoration of memory and other cognitive functions impaired as a result of damaging effects — brain trauma, local and global ischemia, prenatal damage (alcohol, hypoxia). The therapeutic effect of the drug in patients with organic disorders of the central nervous system is manifested starting from the 5th–7th day of treatment. Initially, the anxiolytic and mild stimulating effects present in the spectrum of Noopept® activity are realized, manifested in the reduction or disappearance of anxiety, increased irritability, affective lability, and sleep disturbances.
After 14–20 days of therapy, a positive effect of the drug on cognitive functions, attention, and memory parameters is revealed. Noopept® has a vegetonormalizing effect, helps reduce headaches, orthostatic disturbances, and tachycardia. Upon discontinuation of the drug, no “withdrawal” syndrome is observed. It does not have a damaging effect on internal organs; does not lead to changes in the cellular composition of blood and biochemical parameters of blood and urine; does not possess immunotoxic or teratogenic action, and does not exhibit mutagenic properties.
If you decide to buy noopept (omberacetam) 10mg usa, please note that this pharmacodynamic profile explains why the drug is often used in nootropic and neuroprotective therapy.
Pharmacokinetics
Omberacetam, being absorbed in the gastrointestinal tract, enters the systemic bloodstream unchanged, penetrates the blood-brain barrier, and is detected in the brain in higher concentrations than in the blood. The time to reach maximum concentration averages 15 minutes. The half-life from blood plasma is 0.38 hours. It is partially preserved unchanged and partially metabolized with the formation of phenylacetic acid, phenylacetylproline, and cycloprolylglycine. It has a high relative bioavailability (99.7%), does not accumulate in the body, and does not cause drug dependence.
Omberacetam, being absorbed in the gastrointestinal tract, enters the systemic bloodstream unchanged, penetrates the blood-brain barrier, and is detected in the brain in higher concentrations than in the blood. The time to reach maximum concentration averages 15 minutes. The half-life from blood plasma is 0.38 hours. It is partially preserved unchanged and partially metabolized with the formation of phenylacetic acid, phenylacetylproline, and cycloprolylglycine. It has a high relative bioavailability (99.7%), does not accumulate in the body, and does not cause drug dependence.
Overdose
Specific manifestations of overdose have not been established.
Specific manifestations of overdose have not been established.
Storage Conditions
Store between 2°C and 25°C (36°F to 77°F). Ensure storage requirements are met when you buy noopept (omberacetam) 10mg usa to maintain its effectiveness.
Store between 2°C and 25°C (36°F to 77°F). Ensure storage requirements are met when you buy noopept (omberacetam) 10mg usa to maintain its effectiveness.
Packaging and Release Form
Tablets, 10 mg — 50 pcs with instructions for use are placed in a pack.
Tablets, 10 mg — 50 pcs with instructions for use are placed in a pack.
Dispensing Conditions
Prescription.
Prescription.
Manufacturer
OTCPharm
OTCPharm
Country of Origin
Russia.
Russia.
Before you buy noopept (omberacetam) 10mg usa, consult a healthcare professional and ensure the product is approved for use in your country.
References
- “Noopept Information”. Examine.com. Retrieved 6 April 2017.
- “INN Recommended List 79”. WHO Drug Information. 32 (1): 144. 2018-03-09.
- “Omberacetam”. AdisInsight. Springer Nature Switzerland AG. Retrieved 12 May 2018.
Alternative Names: DVD-111; GVS 111; Noopept
- “Omberacetam”. Inxight. National Center for Advancing Translational Sciences (NCATS). 4QBJ98683M.
- Jump up to: 1 2 Ostrovskaia RU, Gudasheva TA, Voronina TA, Seredenin SB (2002). “[The original novel nootropic and neuroprotective agent noopept]” [The original novel nootropic and neuroprotective agent noopept]. Eksperimental’naia i Klinicheskaia Farmakologiia [Experimental and Clinical Pharmacology] (in Russian). 65 (5): 66–72. PMID 12596521.
- Gudasheva TA, Boyko SS, Ostrovskaya RU, Voronina TA, Akparov VK, Trofimov SS, et al. (1997). “The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine”. European Journal of Drug Metabolism and Pharmacokinetics. 22 (3): 245–252. doi:10.1007/BF03189814. PMID 9358206.
- Gudasheva TA, Koliasnikova KN, Alyaeva AG, Nikolaev SV, Antipova TA, Seredenin SB (December 2022). “Neuroprotective Effect of the Neuropeptide Cycloprolylglycine Depends on AMPA- and TrkB-Receptor Activation”. Doklady. Biochemistry and Biophysics. 507 (1): 264–267. doi:10.1134/S1607672922060047. PMID 36786983.
- Gudasheva TA, Koliasnikova KN, Antipova TA, Seredenin SB (July 2016). “Neuropeptide cycloprolylglycine increases the levels of brain-derived neurotrophic factor in neuronal cells”. Doklady. Biochemistry and Biophysics. 469 (1): 273–276. doi:10.1134/S1607672916040104. PMID 27599510. S2CID 254426990.
- Zainullina LF, Ivanova TV, Sadovnikov SV, Vakhitova YV, Seredenin SB (September 2020). “Cognitive Enhancer Noopept Activates Transcription Factor HIF-1”. Doklady. Biochemistry and Biophysics. 494 (1): 256–260. doi:10.1134/S1607672920050129. PMID 33119829. S2CID 226207175.
- Vakhitova YV, Sadovnikov SV, Borisevich SS, Ostrovskaya RU, A Gudasheva T, Seredenin SB (2016). “Molecular Mechanism Underlying the Action of Substituted Pro-Gly Dipeptide Noopept”. Acta Naturae. 8 (1): 82–89. doi:10.32607/20758251-2016-8-1-82-89. PMC 4837574. PMID 27099787.
- Tardner P (2020). “Finding the optimal dosage fornootropic agent Noopept: An analysis of available literature” (PDF). International Journal of Environmental Science and Technology.
- Neznamov GG, Teleshova ES (March 2009). “Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin”. Neuroscience and Behavioral Physiology. 39 (3): 311–321. doi:10.1007/s11055-009-9128-4. PMID 19234797. S2CID 3348153.
- Miklós K (25 August 2020). “Az új pszichoaktív anyaggá minősített anyagokról vagy vegyületcsoportokról szóló 55/2014. (XII. 30.) EMMI rendelet módosításáról” [About substances classified as new psychoactive substances or 55/2014 on groups of compounds (XII. 30.) amending the EMMI Decree]. Magyarország Hivatalos Lapja [Official Journal of Hungary] (in Hungarian). 194: 6135–6142 (6139). Retrieved 28 April 2021.
- “Ноопепт” [Noopept]. Государственный реестр лекарственных средств [State Register of Medicines] (in Russian).
- “Psychoactive Substances Act 2016”. Legislation.gov.uk.
- Cohen PA, Zakharevich I, Gerona R (March 2020). “Presence of Piracetam in Cognitive Enhancement Dietary Supplements”. JAMA Internal Medicine. 180 (3): 458–459. doi:10.1001/jamainternmed.2019.5507. PMC 6902196. PMID 31764936.
- “Import alert 66-66”. U.S. Food and Drug Administration. 7 September 2021. Archived from the original on October 8, 2009.
- Correll Jr WA (5 February 2019). “Peak Nootropics LLC aka Advanced Nootropics”. FDA Warning letter. U.S. Food and Drug Administration. Archived from the original on September 9, 2019.
- Cohen PA, Avula B, Wang YH, Zakharevich I, Khan I (June 2021). “Five Unapproved Drugs Found in Cognitive Enhancement Supplements”. Neurology. Clinical Practice. 11 (3): e303–e307.
Additional information
| Ingredient | Omberacetam |
|---|---|
| Condition | Brand New |
| Availability | In stock at US warehouse |
Reviews
There are no reviews yet.